Risperdal (risperidone) is an antipsychotic drug designed to treat schizophrenia, bipolar disorder, and symptoms of autism. It received FDA approval for the treatment of schizophrenia in 1994, under a Johnson & Johnson/Janssen Pharmaceuticals patent that would not expire until 2003 (at which point, generic versions of the drug hit the market).

Unfortunately, Risperdal can cause young boys to develop female breast tissue—a condition known as gynecomastia. Drug maker Johnson & Johnson never strengthened Risperdal labels to warn of gynecomastia risks, despite calls from doctors to do so.

Even worse, J&J knew of the gynecomastia risks but manipulated its data and withheld key evidence from the FDA in order to (eventually) obtain approval to market the drug to children.

Hundreds of patients nationwide have filed lawsuits against J&J/Janssen, alleging that the company understood the gynecomastia risks but did not warn consumers of them. Morgan & Morgan is actively involved in Risperdal lawsuits, seeking select cases that match eligibility criteria.

Join the Lawsuit

Johnson & Johnson and Risperdal: A History of Deceit

The FDA approved Risperdal for use by schizophrenics in 1994. From then until December 2003, Johnson & Johnson/Janssen held the patent on the drug and didn’t face any competition from generic versions (which debuted in 2004).

But even with this edge, J&J wanted to widen the drug’s appeal to maximize its profits—despite research showing adverse effects in children and the elderly. Over the next 12 years, the company engaged in myriad deceptive tactics, as covered in great detail by Steven Brill. The following is just the tip of the iceberg.

In 1995, Johnson & Johnson cofounded the Texas Medical Algorithm Project (TMAP), which aimed to sway doctors to prescribe Risperdal to off-label Medicaid patients like kids and senior citizens.

At the same time, the company petitioned the FDA to approve the drug for use by the elderly, but the FDA refused. In 1996, Janssen petitioned the FDA again, this time for use by children. Again, the FDA denied them.

By 1996, Risperdal sales had already reached $589 million a year—nearly three and a half times that of 1994 ($172 million).

In January 1999, the FDA again denied a Janssen request to expand approval to the elderly, stating that the drug maker had “failed to fully explore and explain what appeared to be an excess number of deaths” among elderly Risperdal users.

The following year, the FDA specified that the Risperdal label state it should be used only for schizophrenia, not for the much more general “psychotic disorders.”

Meanwhile, Johnson & Johnson continued to promote the drug for children, offering kickbacks to doctors, creating “back to school” marketing efforts, and even handing out candy and toys with “Risperdal” printed on them.

Hold J&J Accountable

In 2000, Johnson & Johnson learned that 5.5% of boys taking Risperdal long-term eventually developed breasts. The Risperdal label said that this occurred in 0.1% of boys.

By this point, more than a fifth of Risperdal users were children and adolescents.

From 1999 to 2005, the FDA repeatedly warned J&J about promoting Risperdal for use by young people. During this time, the Justice Department says that Janssen promoted Risperdal for use in children and individuals with mental disabilities, despite the company knowing that Risperdal posed “certain health risks to children, including the risk of elevated levels of prolactin, a hormone that can stimulate breast development.” (In 2006, the FDA finally approved Risperdal for use by children and adolescents, specifically those suffering from autism.)

In 2012, Johnson & Johnson settled a Justice Department investigation into its promotion and marketing of Risperdal (and related state investigations, lawsuits, and probes) by paying a $2.2 billion fine, one of the largest in American pharmaceutical history.

But by then, the company had made nearly $30 billion (20 domestic, ten abroad) off the drug. Two billion dollars represented a tiny fraction of this profit—a slap on the wrist given all the kickbacks, unlawful marketing tactics, and data manipulation in which Johnson & Johnson engaged, to the detriment of consumers.

Hundreds if not thousands of boys have allegedly grown breasts from taking Risperdal, and many elderly people have suffered strokes and even died.

Meanwhile, Alex Gorsky, the man responsible for Johnson & Johnson’s Risperdal marketing efforts during this time, was never punished for peddling the drug to children and the elderly. On the contrary, Mr. Gorsky was promoted to CEO of Johnson & Johnson in April 2012. He made $25 million in 2014.

More proof that crime pays: Johnson & Johnson expects its global 2016 profits to total $71 billion.

Fight Back

Studies Link Risperdal to Gynecomastia

Gynecomastia stems from a hormone imbalance and can lead to the growth of male breasts and significant weight gain. It is believed that Risperdal may cause gynecomastia in young male users because it increases levels of the hormone prolactin, which stimulates female breast development and lactation.

The Risperdal-gynecomastia link gained attention from a 2006 study by a Duke psychiatrist that found a strong association between Risperdal and gynecomastia in children and adolescents. The study concluded that when risperidone is administered to adolescents for psychotic symptoms, the drug can increase prolactin levels and lead to gynecomastia.

Another 2006 study on risperidone and gynecomastia drew a similar conclusion, noting that risperidone should be administered to young patients with caution.

A more recent study published in the Journal of Child and Adolescent Psychopharmacology concludes that there is a strong association between risperidone use and gynecomastia in young adult males. Compared to non-users, children and adolescent risperidone users were found to have a gynecomastia risk that was five times higher. The study explicitly notes the “high psychological burden” of gynecomastia.

Traumatic Side Effects Spawn Thousands of Lawsuits

Many young men who have suffered severe and lasting personal injury from Risperdal have filed lawsuits against Johnson & Johnson to seek compensation for physical injury, financial losses, and pain and suffering.

In November 2015, more than 1,500 Risperdal gynecomastia cases were consolidated as part of a mass tort in the Philadelphia Court of Common Pleas. All cases similarly allege that Risperdal caused gynecomastia in young men, and that Janssen did not warn users about this potential side effect.

Early settlements indicate that some Risperdal gynecomastia victims may be in line for significant compensation:

  • In April 2015, a jury awarded a young man who developed size 44D breasts from taking Risperdal $2.5 million in damages. The jury found that Janssen failed to properly warn about the ability of Risperdal to cause gynecomastia.
  • In November 2015, a jury awarded $1.75 million to a man who began taking Risperdal in 2003 for schizophrenia, who also developed gynecomastia.
  • In July 2016, a jury awarded Andrew Yount of Tennessee $70 million in damages. Mr. Yount developed breasts after taking Risperdal as a five-year-old.

According to a Bloomberg News release, Janssen faces around 5,400 Risperdal cases nationwide (not all related to gynecomastia) and has set up a reserve to settle lawsuits.

Johnson & Johnson also faces hundreds of lawsuits over its famous Baby Powder, which has been linked to an increased risk of ovarian cancer.

We Can Help

At Morgan & Morgan, our attorneys help consumers hold drug companies accountable for their dangerous and defective medications. We have decades of experience handling these cases and a lengthy track record of getting victims the compensation they deserve.

Morgan & Morgan has helped more than 200,000 clients win $2 billion in settlements and awards. Importantly, we do not charge a retainer, and only collect a fee if we resolve your case successfully.

If you have suffered side effects after taking Risperdal, please contact us. Don’t wait; these cases are time-sensitive, and you may be entitled to compensation.